JP2017522046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522046A5 JP2017522046A5 JP2017516650A JP2017516650A JP2017522046A5 JP 2017522046 A5 JP2017522046 A5 JP 2017522046A5 JP 2017516650 A JP2017516650 A JP 2017516650A JP 2017516650 A JP2017516650 A JP 2017516650A JP 2017522046 A5 JP2017522046 A5 JP 2017522046A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- aryl
- polynucleotide construct
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002157 polynucleotide Substances 0.000 claims description 154
- 102000040430 polynucleotide Human genes 0.000 claims description 154
- 108091033319 polynucleotide Proteins 0.000 claims description 154
- 125000003118 aryl group Chemical group 0.000 claims description 135
- 125000000217 alkyl group Chemical group 0.000 claims description 109
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 239000002777 nucleoside Substances 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 125000003835 nucleoside group Chemical group 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 33
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 33
- 239000000178 monomer Substances 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 125000005842 heteroatom Chemical group 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 23
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 230000008685 targeting Effects 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 125000000732 arylene group Chemical group 0.000 claims description 13
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- 125000001589 carboacyl group Chemical group 0.000 claims description 11
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 11
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 11
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 11
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 11
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 8
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 8
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 7
- 210000001163 endosome Anatomy 0.000 claims description 7
- 230000002427 irreversible effect Effects 0.000 claims description 7
- -1 5 ′ cap Chemical compound 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229920000620 organic polymer Polymers 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 4
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 4
- 239000001177 diphosphate Substances 0.000 claims description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 4
- 235000011180 diphosphates Nutrition 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 229940014144 folate Drugs 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 4
- 239000001226 triphosphate Substances 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 3
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 229920000359 diblock copolymer Polymers 0.000 claims description 3
- 125000002228 disulfide group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229920003224 poly(trimethylene oxide) Polymers 0.000 claims description 3
- 229920001748 polybutylene Polymers 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 229920000428 triblock copolymer Polymers 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 150000004712 monophosphates Chemical class 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims 7
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 5
- 230000002441 reversible effect Effects 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 description 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 11
- 150000003573 thiols Chemical class 0.000 description 6
- 101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 4
- 102100025483 Retinoid-inducible serine carboxypeptidase Human genes 0.000 description 4
- 125000005529 alkyleneoxy group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009123P | 2014-06-06 | 2014-06-06 | |
| US62/009,123 | 2014-06-06 | ||
| PCT/US2015/034749 WO2015188197A2 (en) | 2014-06-06 | 2015-06-08 | Polynucleotide constructs having bioreversible and non-bioreversible groups |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017522046A JP2017522046A (ja) | 2017-08-10 |
| JP2017522046A5 true JP2017522046A5 (enExample) | 2018-07-19 |
Family
ID=54767614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516650A Pending JP2017522046A (ja) | 2014-06-06 | 2015-06-08 | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170114341A1 (enExample) |
| EP (1) | EP3152308A4 (enExample) |
| JP (1) | JP2017522046A (enExample) |
| CN (1) | CN107109405A (enExample) |
| AU (1) | AU2015269053A1 (enExample) |
| CA (1) | CA2950960A1 (enExample) |
| WO (1) | WO2015188197A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| KR102713216B1 (ko) | 2015-06-25 | 2024-10-02 | 로스웰 엠이 아이엔씨. | 바이오분자 센서들 및 방법들 |
| EP3386517A4 (en) * | 2015-12-08 | 2019-08-07 | Solstice Biologics, Ltd. | POLYNUCLEOTIDE CONSTRUCTS COMPRISING AN AUXILIARY FRACTION RELATED NON-BIOREVERSIBLE TO AN INTERNETOSIDIC PHOSPHATE OR PHOSPHOROTHIOATE |
| JP7109785B2 (ja) | 2016-01-14 | 2022-08-01 | ロズウェル バイオテクノロジーズ，インコーポレイテッド | 分子センサーおよび関連方法 |
| US10712334B2 (en) | 2016-01-28 | 2020-07-14 | Roswell Biotechnologies, Inc. | Massively parallel DNA sequencing apparatus |
| EP3408220A4 (en) | 2016-01-28 | 2019-09-04 | Roswell Biotechnologies, Inc | METHOD AND DEVICE FOR MEASURING ANALYTES USING LARGE CALCULAR MOLECULAR ELECTRONIC SENSOR ARRAYS |
| US10737263B2 (en) | 2016-02-09 | 2020-08-11 | Roswell Biotechnologies, Inc. | Electronic label-free DNA and genome sequencing |
| US10597767B2 (en) | 2016-02-22 | 2020-03-24 | Roswell Biotechnologies, Inc. | Nanoparticle fabrication |
| EP3429618B1 (en) | 2016-03-16 | 2024-02-21 | Amal Therapeutics SA | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| US9829456B1 (en) | 2016-07-26 | 2017-11-28 | Roswell Biotechnologies, Inc. | Method of making a multi-electrode structure usable in molecular sensing devices |
| JP7022443B2 (ja) * | 2016-08-01 | 2022-02-18 | ロズウェル バイオテクノロジーズ，インコーポレイテッド | 分子電子センサーのための修飾ヌクレオチド三リン酸 |
| WO2018035380A1 (en) * | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| MX2019002075A (es) * | 2016-08-23 | 2019-07-01 | Dicerna Pharmaceuticals Inc | Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos. |
| KR20190057345A (ko) | 2016-09-21 | 2019-05-28 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| CN110431148A (zh) | 2017-01-10 | 2019-11-08 | 罗斯威尔生命技术公司 | 用于dna数据存储的方法和系统 |
| US10450565B2 (en) | 2017-01-10 | 2019-10-22 | Arrowhead Pharmaceuticals, Inc. | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use |
| KR102685937B1 (ko) | 2017-01-19 | 2024-07-17 | 로스웰 엠이 아이엔씨. | 2차원 레이어 재료를 포함하는 솔리드 스테이트 시퀀싱 디바이스들 |
| BR112019021520A2 (pt) * | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| KR102692957B1 (ko) | 2017-04-25 | 2024-08-06 | 로스웰 엠이 아이엔씨. | 분자 센서들을 위한 효소 회로들 |
| CN110651182B (zh) | 2017-05-09 | 2022-12-30 | 罗斯威尔生命技术公司 | 用于分子传感器的结合探针电路 |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| EP3674407A4 (en) * | 2017-08-22 | 2022-01-12 | National University Corporation Nagoya University | MODIFIED POLYNUCLEOTIDE |
| EP3676389A4 (en) | 2017-08-30 | 2021-06-02 | Roswell Biotechnologies, Inc | PROCESSIVE ENZYMATIC MOLECULAR ELECTRONIC SENSORS FOR STORING DNA DATA |
| WO2019075100A1 (en) | 2017-10-10 | 2019-04-18 | Roswell Biotechnologies, Inc. | METHODS, APPARATUS AND SYSTEMS FOR STORING DNA DATA WITHOUT AMPLIFICATION |
| EP3684377B1 (en) | 2017-10-20 | 2022-12-07 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis b infection |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| CN110959011B (zh) * | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| EP3710588A4 (en) | 2018-01-16 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS TO INHIBIT ALDH2 EXPRESSION |
| AU2019222767A1 (en) | 2018-02-14 | 2020-08-27 | Deep Genomics Incorporated | Oligonucleotide therapy for Wilson disease |
| CA3098623A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | ｓｉＲＮＡ複合体及びその調製方法と使用 |
| AU2019360216A1 (en) * | 2018-10-17 | 2021-05-13 | Tallac Therapeutics, Inc. | Immunomodulating polynucleotide conjugates and methods of use |
| US11249941B2 (en) * | 2018-12-21 | 2022-02-15 | Palo Alto Research Center Incorporated | Exabyte-scale data storage using sequence-controlled polymers |
| JP7507495B2 (ja) * | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN112423795B (zh) * | 2018-12-28 | 2026-06-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020167593A1 (en) | 2019-02-12 | 2020-08-20 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for inhibiting expression of cyp27a1 |
| AU2020252560A1 (en) | 2019-04-04 | 2021-10-28 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795280B (zh) * | 2019-05-24 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2020286462B2 (en) | 2019-06-06 | 2026-07-02 | Arrowhead Pharmaceuticals, Inc. | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) |
| CN112390835A (zh) * | 2019-08-14 | 2021-02-23 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
| JP2022546055A (ja) * | 2019-08-29 | 2022-11-02 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 化合物、薬物複合体及びその調製方法と使用 |
| US20220389430A1 (en) | 2019-10-02 | 2022-12-08 | Dicema Pharmaceuticals, Inc. | Chemical modifications of small interfering rna with minimal fluorine content |
| CA3164050A1 (en) | 2019-12-09 | 2021-06-17 | Empirico Inc. | Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases |
| EP4081639A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| EP4081217A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| CA3172117A1 (en) | 2020-03-18 | 2021-09-23 | Bob D. Brown | Compositions and methods for inhibiting angptl3 expression |
| JP2023537499A (ja) | 2020-08-04 | 2023-09-01 | ディセルナ ファーマシューティカルズ インコーポレイテッド | オリゴヌクレオチドの全身送達 |
| TW202221120A (zh) | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
| KR20250077604A (ko) | 2020-08-05 | 2025-05-30 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| JP2023536999A (ja) | 2020-08-05 | 2023-08-30 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎患者のオリゴヌクレオチド処置 |
| TW202228729A (zh) | 2020-10-08 | 2022-08-01 | 美商戴瑟納製藥股份有限公司 | 選擇性遞送寡核苷酸至膠細胞 |
| WO2022081867A1 (en) * | 2020-10-14 | 2022-04-21 | North Carolina State University | Compositions and methods for drug delivery |
| CN115209922A (zh) * | 2021-01-28 | 2022-10-18 | 南京桦冠生物技术有限公司 | 缀合物及其用途 |
| IL305634A (en) | 2021-03-05 | 2023-11-01 | Dicerna Pharmaceuticals Inc | Rnai conjugates and uses thereof |
| KR20230171431A (ko) | 2021-04-14 | 2023-12-20 | 다이서나 파마수이티컬, 인크. | Pnpla3 발현을 조절하기 위한 조성물 및 방법 |
| AU2022384619A1 (en) | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| JP7877458B2 (ja) | 2021-12-01 | 2026-06-22 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ａｐｏｃ３発現を調節するための組成物及び方法 |
| WO2023113038A1 (ja) * | 2021-12-17 | 2023-06-22 | リードファーマ株式会社 | オリゴヌクレオチドの製造方法 |
| IL315546A (en) | 2022-03-16 | 2024-11-01 | Empirico Inc | GALNAC compositions to improve siRNA bioavailability |
| JP2025512445A (ja) | 2022-04-15 | 2025-04-17 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｓｃａｐ活性を調節するための組成物及び方法 |
| WO2024093947A1 (zh) * | 2022-10-31 | 2024-05-10 | 大睿生物医药科技(上海)有限公司 | 向细胞内递送siRNA的前药 |
| CN115925586A (zh) * | 2022-11-01 | 2023-04-07 | 青岛蓝谷多肽生物医药科技有限公司 | 一种靶向psma的母体及其衍生物的制备方法 |
| WO2024097310A2 (en) * | 2022-11-01 | 2024-05-10 | Impilo Therapeutics, Inc. | Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| CN118852442A (zh) | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| CN116925160B (zh) * | 2023-09-15 | 2023-12-08 | 天津全和诚科技有限责任公司 | 一种GalNAc含糖环中间体及其制备方法 |
| WO2025235911A2 (en) * | 2024-05-09 | 2025-11-13 | Wave Life Sciences Ltd. | Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto |
| WO2026117631A2 (en) | 2024-11-26 | 2026-06-04 | City Therapeutics, Inc. | Factor xi rnai agent compositions and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2651453C (en) * | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| EP2342340A1 (en) * | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| US20120142763A1 (en) * | 2009-06-01 | 2012-06-07 | The Regents Of The University Of California | Nucleic acid delivery compositions and methods of use thereof |
| JP2015529073A (ja) * | 2012-08-20 | 2015-10-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物可逆性基を有するポリヌクレオチド |
| CN106061981A (zh) * | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
-
2015
- 2015-06-08 CN CN201580041889.0A patent/CN107109405A/zh active Pending
- 2015-06-08 AU AU2015269053A patent/AU2015269053A1/en not_active Abandoned
- 2015-06-08 US US15/315,608 patent/US20170114341A1/en not_active Abandoned
- 2015-06-08 JP JP2017516650A patent/JP2017522046A/ja active Pending
- 2015-06-08 EP EP15803887.7A patent/EP3152308A4/en not_active Withdrawn
- 2015-06-08 CA CA2950960A patent/CA2950960A1/en not_active Abandoned
- 2015-06-08 WO PCT/US2015/034749 patent/WO2015188197A2/en not_active Ceased
-
2020
- 2020-02-03 US US16/780,204 patent/US20200392498A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3062897T3 (en) | Compositions and methods of treating muscle dystrophy | |
| US20200392498A1 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
| EP3406730B1 (en) | Novel single chemical entities and methods for delivery of oligonucleotides | |
| AU2009246329B8 (en) | Micellic assemblies | |
| AU2016202354B2 (en) | Chemical modifications of monomers and oligonucleotides with cycloaddition | |
| AU2009246327B2 (en) | Diblock copolymers and polynucleotide complexes thereof for delivery into cells | |
| US20160257961A1 (en) | Polynucleotide constructs having disulfide groups | |
| JP2021507709A5 (enExample) | ||
| US20180303864A1 (en) | Polynucleotides having bioreversible groups | |
| JP2016537027A5 (enExample) | ||
| IL274503B2 (en) | Nucleic acids for inhibiting expression of lpa in a cell | |
| JP2013531981A (ja) | 選択的オリゴヌクレオチド修飾の方法 | |
| JP2008220366A (ja) | 修飾型ｐｎａ／ｒｎａ複合体 | |
| JP2020518552A5 (enExample) | ||
| JP6773677B2 (ja) | 改善されたジスルフィド含有アルキン連結剤 | |
| CN104114704A (zh) | 高效率的纳米颗粒型双螺旋寡rna结构体及其制备方法 | |
| KR20140037449A (ko) | 히알루론산-핵산 접합체 및 이를 포함하는 핵산 전달용 조성물 | |
| WO2002087497A3 (en) | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use | |
| JP2006067889A5 (enExample) | ||
| WO2006042269A3 (en) | Lipopolymer conjugates | |
| US20150275206A1 (en) | Polymer conjugates for delivery of biologically active agents | |
| JP4712333B2 (ja) | ハイブリッド多糖系キャリアーを用いる核酸類の導入方法。 | |
| JP7740708B2 (ja) | ポリデオキシアデニル酸が連結した短鎖ＣｐＧ含有オリゴデオキシヌクレオチド、該オリゴデオキシヌクレオチドを含有する複合体、及びその用途 | |
| JP2005204612A (ja) | 新規な遺伝子導入法 | |
| US20240167035A1 (en) | RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use |